Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice

Area of Science:

• Neuroscience
• Immunology
• Radiology

Background:

• Fingolimod (FTY720) is an S1P receptor modulator used for relapsing-remitting multiple sclerosis (RRMS).
• FTY720's potential neuroprotective effects beyond immunosuppression are debated.
• In vivo diffusion tensor imaging (DTI) offers noninvasive biomarkers for axonal injury and demyelination.

Purpose of the Study:

• To assess the neuroprotective effects of FTY720 in a mouse model of multiple sclerosis (MS).
• To evaluate FTY720's impact on axonal and myelin integrity using in vivo DTI.
• To determine the efficacy of prophylactic and therapeutic FTY720 treatment in experimental autoimmune encephalomyelitis (EAE).

Main Methods:

• Experimental autoimmune encephalomyelitis (EAE) induced in C57BL/6 mice using MOG(35-55) peptide.
• Administration of FTY720 (3 and 10 mg/kg) prophylactically and therapeutically.
• Daily clinical scoring and end-point in vivo DTI for assessing disease progression and neuroprotection.

Main Results:

• Prophylactic FTY720 significantly suppressed EAE onset and prevented axonal/myelin damage.
• Therapeutic FTY720 reduced disease severity and improved DTI metrics (axial and radial diffusivity) toward control levels, though not statistically significant.
• In vivo DTI-derived diffusivity correlated with clinical scores in EAE mice.

Conclusions:

• FTY720 demonstrates neuroprotective capabilities in a preclinical MS model, particularly when administered prophylactically.
• In vivo DTI serves as a valuable tool for evaluating neuroprotection in drug development for MS.
• Further research is warranted to fully elucidate FTY720's therapeutic neuroprotective mechanisms.